Skip to main content

Articles

Page 41 of 60

  1. Visceral fat, including epicardial fat (EF) is recognized as a responsible factor of cardiovascular disease. The aim of this study was to investigate the relationship between EF and diabetes in Korean men.

    Authors: Hyejin Chun, Eunkyung Suh, A Ri Byun, Hae Ran Park and Kyung Won Shim
    Citation: Cardiovascular Diabetology 2015 14:46
  2. We have previously shown that in hypertensive Dahl salt-sensitive (DS) rats, impaired endothelium-dependent relaxation to acetylcholine and to insulin is mechanistically linked to up-regulation of angiotensin ...

    Authors: Ming-Sheng Zhou, Chang Liu, Runxia Tian, Akira Nishiyama and Leopoldo Raij
    Citation: Cardiovascular Diabetology 2015 14:45
  3. To investigate the effect of low blood glucose on thrombin generation and fibrin clot properties in type 2 diabetes (T2DM).

    Authors: Grzegorz Gajos, Malgorzata Konieczynska, Jaroslaw Zalewski and Anetta Undas
    Citation: Cardiovascular Diabetology 2015 14:44
  4. Left ventricular hypertrophy (LVH) is prevalent in patients with type 2 diabetes mellitus (T2DM). Recent studies show that an increase in albumin-adjusted serum calcium level is associated with an elevated ris...

    Authors: Junfeng Li, Nan Wu, Yintao Li, Kuanping Ye, Min He and Renming Hu
    Citation: Cardiovascular Diabetology 2015 14:43
  5. The aim of this study was to clarify whether common single nucleotide polymorphisms (SNPs) of the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) gene (rs1801282) and the Peroxisome Proliferator-Activate...

    Authors: Peter Kruzliak, Andreana P Haley, Jovana Nikolajevic Starcevic, Ludovit Gaspar and Daniel Petrovic
    Citation: Cardiovascular Diabetology 2015 14:42
  6. Impaired coronary microcirculation is associated with a poor prognosis in patients with type 2 diabetes. In the absence of stenosis of major coronary arteries, coronary flow reserve (CFR) reflects coronary mic...

    Authors: Rebekka Faber, Mette Zander, Adam Pena, Marie M Michelsen, Naja D Mygind and Eva Prescott
    Citation: Cardiovascular Diabetology 2015 14:41
  7. Obesity is an excessive accumulation of fat frequently, but not always, associated with health problems, mainly type 2 diabetes and cardiovascular disease. During a positive energy balance, as caused by excess...

    Authors: Elena Torres-Perez, Monica Valero, Beatriz Garcia-Rodriguez, Yolanda Gonzalez-Irazabal, Pilar Calmarza, Luisa Calvo-Ruata, Carmen Ortega, Maria Pilar Garcia-Sobreviela, Alejandro Sanz-Paris, Jose Maria Artigas, Javier Lagos and Jose M Arbones-Mainar
    Citation: Cardiovascular Diabetology 2015 14:40
  8. The health impact of dietary replacement of carbohydrates with protein for patients with type 2 diabetes is still debated. This study aimed to investigate the association between dietary substitution of carboh...

    Authors: Marjo JE Campmans-Kuijpers, Ivonne Sluijs, Ute Nöthlings, Heinz Freisling, Kim Overvad, Elisabete Weiderpass, Guy Fagherazzi, Tilman Kühn, Verena A Katzke, Amalia Mattiello, Emily Sonestedt, Giovanna Masala, Claudia Agnoli, Rosario Tumino, Annemieke MW Spijkerman, Aurelio Barricarte…
    Citation: Cardiovascular Diabetology 2015 14:39
  9. Diabetes and chronic kidney disease (CKD) are independent predictors of death and cardiovascular events and their concomitant prevalence has increased in recent years. The aim of this study was to characterize...

    Authors: Lucia Cea Soriano, Saga Johansson, Bergur Stefansson and Luis A García Rodríguez
    Citation: Cardiovascular Diabetology 2015 14:38
  10. Left ventricular (LV) longitudinal systolic dysfunction has been identified even in asymptomatic patients with diabetes mellitus (DM) and preserved LV ejection fraction (LVEF). However, its relevant clinical f...

    Authors: Yasuhide Mochizuki, Hidekazu Tanaka, Kensuke Matsumoto, Hiroyuki Sano, Hiromi Toki, Hiroyuki Shimoura, Junichi Ooka, Takuma Sawa, Yoshiki Motoji, Keiko Ryo, Yushi Hirota, Wataru Ogawa and Ken-ichi Hirata
    Citation: Cardiovascular Diabetology 2015 14:37
  11. The associations between urine uric acid excretion (UUAE) and chronic kidney disease (CKD)/atherosclerosis have not been investigated. Our aims were to investigate the relationships between UUAE and CKD and ca...

    Authors: Lian-Xi Li, Ai-Ping Wang, Rong Zhang, Ting-Ting Li, Jun-Wei Wang, Yu-Qian Bao and Wei-Ping Jia
    Citation: Cardiovascular Diabetology 2015 14:36
  12. Although recent animal studies have suggested that angiopoietin-like protein 2 (ANGPTL2), a novel inflammatory adipokine, is likely to be involved in the pathogenesis of atherosclerosis, in rodents, little is ...

    Authors: Chang Hee Jung, Woo Je Lee, Min Jung Lee, Yu Mi Kang, Jung Eun Jang, Jaechan Leem, Yoo La Lee, So Mi Seol, Hae Kyeong Yoon and Joong-Yeol Park
    Citation: Cardiovascular Diabetology 2015 14:35
  13. The editors of Cardiovascular Diabetology would like to thank all our reviewers who have contributed to the journal in Volume 13 (2014).

    Authors: Enrique Fisman and Alexander Tenenbaum
    Citation: Cardiovascular Diabetology 2015 14:34
  14. Cardiovascular disease (CVD) is the leading cause of mortality among subjects with type 2 diabetes (T2D), and diabetic retinopathy (DR) has been associated with an increased risk for CVD. The present study was...

    Authors: Núria Alonso, Alicia Traveset, Esther Rubinat, Emilio Ortega, Nuria Alcubierre, Jordi Sanahuja, Marta Hernández, Angels Betriu, Carmen Jurjo, Elvira Fernández and Didac Mauricio
    Citation: Cardiovascular Diabetology 2015 14:33

    The Correction to this article has been published in Cardiovascular Diabetology 2018 17:49

  15. Fibroblast growth factor 21 (FGF21) is an emerging metabolic regulator associated with glucose and lipid metabolism, and it is still unclear whether FGF21 is related to atherosclerosis. Here, we explored the p...

    Authors: Xiaoyan Zhang, Yanyun Hu, Hui Zeng, Lianxi Li, Jungong Zhao, Jun Zhao, Fang Liu, Yuqian Bao and Weiping Jia
    Citation: Cardiovascular Diabetology 2015 14:32
  16. Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diab...

    Authors: Stijn A Peeters, Lian Engelen, Jacqueline Buijs, Nish Chaturvedi, John H Fuller, Casper G Schalkwijk and Coen D Stehouwer
    Citation: Cardiovascular Diabetology 2015 14:31

    The Erratum to this article has been published in Cardiovascular Diabetology 2015 14:128

  17. We have noted in previous work, in a variety of inflammatory diseases, where iron dysregulation occurs, a strong tendency for erythrocytes to lose their normal discoid shape and to adopt a skewed morphology (a...

    Authors: Etheresia Pretorius, Janette Bester, Natasha Vermeulen, Sajee Alummoottil, Prashilla Soma, Antoinette V Buys and Douglas B Kell
    Citation: Cardiovascular Diabetology 2015 14:30
  18. Glucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase-4 (DPP4) inhibitors are a newer class of antidiabetics named as incretin-based therapy. In addition to the homeostatic control of glucose, the i...

    Authors: Xiaoyan Zhou, Chin-hu Huang, Julie Lao, Alessandro Pocai, Gail Forrest, Olga Price, Sophie Roy, David E Kelley, Kathleen A Sullivan and Michael J Forrest
    Citation: Cardiovascular Diabetology 2015 14:29
  19. The diagnosis of diabetes has important clinic implications for the prevention and management of cardiometabolic disorders. We aimed to investigate the awareness, treatment and control of hypertension and dysl...

    Authors: Tiange Wang, Yu Xu, Min Xu, Weiqing Wang, Yufang Bi, Jieli Lu, Meng Dai, Di Zhang, Lin Ding, Baihui Xu, Jichao Sun, Wenhua Zhao, Yong Jiang, Limin Wang, Yichong Li, Mei Zhang…
    Citation: Cardiovascular Diabetology 2015 14:28
  20. Glucagon-like peptide-1 is an incretin hormone essential for normal human glucose homeostasis. Expression of the glucagon-like peptide-1 receptor in the myocardium has fuelled growing interest in the direct an...

    Authors: Aung Myat, Satpal Arri, Deepak L Bhatt, Bernard J Gersh, Simon R Redwood and Michael S Marber
    Citation: Cardiovascular Diabetology 2015 14:27
  21. Angiotensin II type 1 receptor (AT1R) blockers have beneficial effects on neurovascular complications in diabetes and in organ’s protection against ischemic episodes. The present study examines whether the AT1...

    Authors: Aurore Danigo, Mohamad Nasser, Flavien Bessaguet, James Javellaud, Nicole Oudart, Jean-Michel Achard and Claire Demiot
    Citation: Cardiovascular Diabetology 2015 14:26
  22. Basic studies have shown that glucagon-like peptide-1 (GLP-1) analogs exert a direct protective effect on the vascular endothelium in addition to their indirect effects on postprandial glucose and lipid metabo...

    Authors: Keiichi Torimoto, Yosuke Okada, Hiroko Mori, Takashi Otsuka, Mayuko Kawaguchi, Megumi Matsuda, Fumi Kuno, Kei Sugai, Satomi Sonoda, Maiko Hajime, Kenichi Tanaka, Tadashi Arao and Yoshiya Tanaka
    Citation: Cardiovascular Diabetology 2015 14:25
  23. Paradoxically, beneficial effects of overweight and obesity on survival have been found in patients after cardiovascular events such as acute myocardial infarction (AMI). This obesity paradox has not been anal...

    Authors: Miriam Giovanna Colombo, Christa Meisinger, Ute Amann, Margit Heier, Wolfgang von Scheidt, Bernhard Kuch, Annette Peters and Inge Kirchberger
    Citation: Cardiovascular Diabetology 2015 14:24
  24. Both non-alcoholic fatty liver disease (NAFLD) and Type 2 diabetes increase the risk of developing cardiovascular disease. The metabolic processes underlying NAFLD and Type 2 diabetes are part of an integrated...

    Authors: Sophie Cassidy, Kate Hallsworth, Christian Thoma, Guy A MacGowan, Kieren G Hollingsworth, Christopher P Day, Roy Taylor, Djordje G Jakovljevic and Michael I Trenell
    Citation: Cardiovascular Diabetology 2015 14:23
  25. The prevalence of obesity has dramatically increased worldwide and has attracted rising attention, but the mechanism is still unclear. Previous studies revealed that transient receptor potential vanilloid 1 (T...

    Authors: Jian Chen, Li Li, Yingsha Li, Xia Liang, Qianqian Sun, Hao Yu, Jian Zhong, Yinxing Ni, Jing Chen, Zhigang Zhao, Peng Gao, Bin Wang, Daoyan Liu, Zhiming Zhu and Zhencheng Yan
    Citation: Cardiovascular Diabetology 2015 14:22
  26. To assess glucose and triglyceride excursions 2 hours after the ingestion of a standardized meal and their associations with clinical characteristics and cardiovascular complications in individuals with diabetes.

    Authors: Bárbara P Riboldi, Vivian C Luft, Cristina D de Castilhos, Letícia O de Cardoso, Maria I Schmidt, Sandhi M Barreto, Maria F de Sander, Sheila M Alvim and Bruce B Duncan
    Citation: Cardiovascular Diabetology 2015 14:21
  27. Experimental studies have shown that high free fatty acid (FFA) and low adiponectin (ADIPO) levels are involved in the mechanisms by which adiposity promotes insulin resistance (IR). However, no previous clini...

    Authors: Aida Medina-Urrutia, Carlos Posadas-Romero, Rosalinda Posadas-Sánchez, Esteban Jorge-Galarza, Teresa Villarreal-Molina, María del Carmen González-Salazar, Guillermo Cardoso-Saldaña, Gilberto Vargas-Alarcón, Margarita Torres-Tamayo and Juan Gabriel Juárez-Rojas
    Citation: Cardiovascular Diabetology 2015 14:20
  28. Diabetes is a risk factor for the development of cardiovascular diseases with impaired angiogenesis. We have previously shown that platelet-derived growth factor C (PDGF-C) and its receptor, PDGF receptor α (P...

    Authors: Junji Moriya and Napoleone Ferrara
    Citation: Cardiovascular Diabetology 2015 14:19
  29. As a new anti-diabetic medicine, Liraglutide (LIRA), one of GLP-1 analogues, has been found to have an anti-atherosclerotic effect. Since vascular smooth muscle cells (VSMCs) play pivotal roles in the occurren...

    Authors: Lili Shi, Ye Ji, Xiaoyan Jiang, Lihong Zhou, Ying Xu, Yanbo Li, Wei Jiang, Ping Meng and Xiaomin Liu
    Citation: Cardiovascular Diabetology 2015 14:18
  30. Diabetic cardiomyopathy is defined as ventricular dysfunction initiated by alterations in cardiac energy substrates in the absence of coronary artery disease and hypertension. In addition to the demonstrated b...

    Authors: Jesús Fuentes-Antrás, Belén Picatoste, Elisa Ramírez, Jesús Egido, José Tuñón and Óscar Lorenzo
    Citation: Cardiovascular Diabetology 2015 14:17
  31. The aim of this study was to investigate the associations of two nontraditional glycemic markers, glycated albumin (GA) and 1,5-anhydroglucitol (1,5-AG), as well as glycated hemoglobin A1c (HbA1c) with coronar...

    Authors: Xiaojing Ma, Xiang Hu, Jian Zhou, Yaping Hao, Yuqi Luo, Zhigang Lu, Yuqian Bao and Weiping Jia
    Citation: Cardiovascular Diabetology 2015 14:16
  32. Although antiplatelet therapy involving clopidogrel is a standard treatment for preventing cardiovascular events after coronary stent implantation, patients can display differential responses. Here, we assesse...

    Authors: Claudia Schuette, Daniel Steffens, Marco Witkowski, Caroline Stellbaum, Peter Bobbert, Heinz-Peter Schultheiss and Ursula Rauch
    Citation: Cardiovascular Diabetology 2015 14:15
  33. The aim of this study was to analyse which factors predict the real-world macro-/microvascular event, hospitalisation and death risk in patients with type 2 diabetes mellitus. Furthermore, we aimed to investig...

    Authors: Thomas Wilke, Sabrina Mueller, Antje Groth, Andreas Fuchs, Lisa Seitz, Joachim Kienhöfer, Ulf Maywald, Rainer Lundershausen and Martin Wehling
    Citation: Cardiovascular Diabetology 2015 14:14
  34. Metformin is the first line drug for patients diagnosed with type-2 diabetes; however, the impact of different treatment escalation strategies after metformin failure has thus far not been investigated in a re...

    Authors: Anselm K Gitt, Peter Bramlage, Steffen Schneider and Diethelm Tschöpe
    Citation: Cardiovascular Diabetology 2015 14:13
  35. Overweight or obesity contributes to the development of type 2 diabetes mellitus (T2DM) and increases cardiovascular risk. Exenatide, a glucagon-like peptide-1 receptor agonist, significantly reduces glycated ...

    Authors: Lawrence Blonde, Richard Pencek and Leigh MacConell
    Citation: Cardiovascular Diabetology 2015 14:12
  36. This study evaluated the effect of empagliflozin on postprandial glucose (PPG) and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM).

    Authors: Rimei Nishimura, Yuko Tanaka, Kazuki Koiwai, Kohei Inoue, Thomas Hach, Afshin Salsali, Søren S Lund and Uli C Broedl
    Citation: Cardiovascular Diabetology 2015 14:11
  37. To evaluate the association of treatment with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide and/or insulin on macrovascular outcomes in patients with type 2 diabetes (T2DM).

    Authors: Sanjoy K Paul, Kerenaftali Klein, David Maggs and Jennie H Best
    Citation: Cardiovascular Diabetology 2015 14:10
  38. Visceral fat accumulation is a major etiological factor in the progression of type 2 diabetes mellitus and atherosclerosis. We described previously visceral fat accumulation and multiple cardiovascular risk fa...

    Authors: Shiro Fukuda, Ayumu Hirata, Hitoshi Nishizawa, Hirofumi Nagao, Susumu Kashine, Takekazu Kimura, Kana Inoue, Yuya Fujishima, Masaya Yamaoka, Junji Kozawa, Tetsuhiro Kitamura, Tetsuyuki Yasuda, Norikazu Maeda, Akihisa Imagawa, Tohru Funahashi and Iichiro Shimomura
    Citation: Cardiovascular Diabetology 2015 14:8
  39. The cardio ankle vascular index (CAVI) is a new index of the overall stiffness of the artery from the origin of the aorta to the ankle. This index can estimate the risk of atherosclerosis. We aimed to find the...

    Authors: Manuel Ángel Gómez-Marcos, José Ignacio Recio-Rodríguez, María Carmen Patino-Alonso, Cristina Agudo-Conde, Leticia Gómez-Sánchez, Marta Gomez-Sanchez, Emiliano Rodríguez-Sanchez, Jose Angel Maderuelo-Fernandez and Luís García-Ortiz
    Citation: Cardiovascular Diabetology 2015 14:7
  40. A long-term high-fat/cholesterol (HFC) diet leads to insulin resistance (IR), which is associated with inflammation, atherosclerosis (AS), cardiac sympathovagal imbalance, and cardiac dysfunction. Peroxisome p...

    Authors: Pan Yongming, Cai Zhaowei, Ma Yichao, Zhu Keyan, Chen Liang, Chen Fangming, Xu Xiaoping, Ma Quanxin and Chen Minli
    Citation: Cardiovascular Diabetology 2015 14:6
  41. Oxidative stress is involved in development of diabetes complications. Extracellular superoxide dismutase (EC-SOD, SOD3) is a major extracellular antioxidant enzyme and is highly expressed in arterial walls. A...

    Authors: Kamel Mohammedi, Naïma Bellili-Muñoz, Stefan L Marklund, Fathi Driss, Hervé Le Nagard, Thiago A Patente, Frédéric Fumeron, Ronan Roussel, Samy Hadjadj, Michel Marre and Gilberto Velho
    Citation: Cardiovascular Diabetology 2015 14:845
  42. Obesity, type 2 diabetes and atrial fibrillation (AF) are closely associated, but the underlying mechanisms are not fully understood. We aimed to explore associations between body mass index (BMI) or weight ch...

    Authors: Irene Grundvold, Johan Bodegard, Peter M Nilsson, Bodil Svennblad, Gunnar Johansson, Carl Johan Östgren and Johan Sundström
    Citation: Cardiovascular Diabetology 2015 14:5
  43. Diabetes increases the risk of heart failure but the underlying mechanisms leading to diabetic cardiomyopathy are poorly understood. Left ventricle diastolic dysfunction (LVDD) is one of the earliest cardiac c...

    Authors: Ricardo Fontes-Carvalho, Ricardo Ladeiras-Lopes, Paulo Bettencourt, Adelino Leite-Moreira and Ana Azevedo
    Citation: Cardiovascular Diabetology 2015 14:4
  44. Hypoadiponectinemia is a well-known state associated with metabolic syndrome (MetS) and insulin resistance (IR). Recently aldosterone has been highly associated with high blood pressure, and may thus be a poss...

    Authors: Jui-Kun Chiang, Chi-Ling Chen, Feng-Yu Tseng, Yu-Chiao Chi, Kuo-Chin Huang and Wei-Shiung Yang
    Citation: Cardiovascular Diabetology 2015 14:3
  45. Advanced glycation end products (AGEs) consist of heterogenous group of macroprotein derivatives, which are formed by non-enzymatic reaction between reducing sugars and amino groups of proteins, lipids and nuc...

    Authors: Sho-ichi Yamagishi, Kei Fukami and Takanori Matsui
    Citation: Cardiovascular Diabetology 2015 14:2
  46. We have previously shown that serum levels of glyceraldehyde-derived advanced glycation end products (Gly-AGEs) are elevated under oxidative stress and/or diabetic conditions and associated with insulin resist...

    Authors: Takanori Matsui, Eriko Oda, Yuichiro Higashimoto and Sho-ichi Yamagishi
    Citation: Cardiovascular Diabetology 2015 14:1
  47. Endothelial dysfunction is a crucial early phenomenon in vascular diseases linked to diabetes mellitus and associated to enhanced oxidative stress. There is increasing evidence about the role for pro-inflammat...

    Authors: Susana Vallejo, Erika Palacios, Tania Romacho, Laura Villalobos, Concepción Peiró and Carlos F Sánchez-Ferrer
    Citation: Cardiovascular Diabetology 2014 13:158
  48. Vascular calcified plaque, a measure of subclinical cardiovascular disease (CVD), is unlikely to be limited to a single vascular bed in patients with multiple risk factors. Consideration of vascular calcified ...

    Authors: Amanda J Cox, Fang-Chi Hsu, Subhashish Agarwal, Barry I Freedman, David M Herrington, J Jeffrey Carr and Donald W Bowden
    Citation: Cardiovascular Diabetology 2014 13:160
  49. Increasing numbers of type 2 diabetic and obese patients with enhanced rates of cardiovascular complications require surgical interventions, however they have a higher incidence of perioperative haemodynamic c...

    Authors: Carol T Bussey, Anne E de Leeuw and Regis R Lamberts
    Citation: Cardiovascular Diabetology 2014 13:161

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions